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Abstract 
 
Five G protein-coupled receptors (GPCRs) have been identified to be activated by free fatty acids 
(FFA). Among them, FFA1 (GPR40) and FFA4 (GPR120) bind long-chain fatty acids, FFA2 (GPR43) 
and FFA3 (GPR41) bind short-chain fatty acids and GPR84 binds medium-chain fatty acids. Free 
fatty acid receptors have now emerged as potential targets for the treatment of diabetes, obesity and 
immune diseases. The recent progress in crystallography of GPCRs has now enabled the elucidation 
of the structure of FFA1 and provided reliable templates for homology modelling of other FFA 
receptors. Analysis of the crystal structure and improved homology models, along with mutagenesis 
data and structure activity, highlighted an unusual arginine charge pairing interaction in FFA1-3 for 
receptor modulation, distinct structural features for ligand binding to FFA1 and FFA4 and an arginine 
of the second extracellular loop as a possible anchoring point for FFA at GPR84. Structural data will 
be helpful for searching novel small molecule modulators at the FFA receptors.       
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Introduction 
 
The free fatty acid receptors are members of the rhodopsin family of G protein-coupled receptors 
(GPCRs) and relay binding of endogenous free fatty acids at the cell surface into intracellular 
activation of a heterotrimeric G protein. Currently, five GPCRs have been identified to bind free fatty 
acids with a different level of specificity. The free fatty acid receptor 1 (FFA1), previously known as 
GPR40, binds preferably long- and medium-chain fatty acids with more than 12 carbon atoms (Briscoe 
et al. 2006;Itoh and Hinuma. 2005). The free fatty acid receptor 2 (FFA2), previously known as 
GPR43, and the free fatty acid receptor 3 (FFA3), known as GPR41, respond to short-chain fatty 
acids with less than 5 carbon atoms (Brown et al. 2003). FFA1-3 have more than 30 % of sequence 
identity and belong to the branch of nucleotide receptors in the phylogenetic tree of the rhodopsin 
family of GPCRs (Figure 1). The free fatty acid receptor four (FFA4), also known as GPR120 has a 
preference to bind long-chain fatty acids (Hirasawa et al. 2005), like FFA1, but has a substantially low 
sequence identity with FFA1 (< 19%) and other members of the family. Phylogenetically, FFA4 is 
clustered with several orphan receptors.  The last receptor, GPR84 is activated by medium-chain fatty 
acids with 7-12 carbon atoms (Wang et al. 2006), has low similarity with FFA1-4 (< 21%) and is 
branched with the prostanoid receptors. Since free fatty acid signaling is a molecular messenger 
system regulating energy storage, metabolism and inflammation, these receptors are thought to be 
involved in numerous metabolic and inflammatory conditions such as obesity, type 2 diabetes, 
atherosclerosis, cardiovascular diseases, ulcerative colitis, Crohn’s disease and irritable bowel 
disease (Ulven. 2012;Dranse et al. 2013;Milligan et al. 2014;Bindels et al. 2013).  
Knowledge of the receptor three-dimensional structure is crucial for an understanding of the molecular 
mechanisms underlying diseases as well as for structure-based design of small molecule modulators. 
The FFA receptors share the overall topological structure typical of GPCRs: seven alpha-helices that 
cross the cell membrane and are connected by three extracellular and intracellular loops, the N 
terminus in the extracellular side and the C terminus in the intracellular side of the receptors. The 
recent breakthrough in structural biology of GPCRs enabled crystallographic structures for 27 
receptors of the rhodopsin family of GPCRs, including the FFA1 receptor.  A FFA1 structure is solved 
in the complex with the ago-allosteric ligand, TAK-875 (Srivastava et al. 2014) and provides a crucial 
point to study ligand recognition at FFA1. However, FFA2, FFA3, GPR120 and GPR84 have not been 
yet crystallized. The crystallization of GPCRs remains a challenging and long process, and it will take 
years to get the structure of other free fatty acid receptors. Solving GPCR structures in the complex 
with various ligands is also labor-intensive and time-consuming. Therefore, computational techniques 
such as homology modelling and ligand docking will play an important role in mapping ligand-receptor 
contacts and providing working hypotheses for site-directed mutagenesis of the receptors.  
Homology modelling in combination with mutagenesis data enables indirect structural information and 
has been proven to be insightful in an understanding of ligand-protein interactions in many GPCRs. 
In homology modeling the structure of the protein is constructed from its amino acid sequence and 
an experimental structure of a related homologous protein. A detailed procedure of GPCR homology 
modelling is provided in the recent article by Costanzi (Costanzi. 2012). Crystal structures as well as 
homology models of GPCRs serve as a basis to explore ligand binding through various molecular 
docking protocols. Ligand docking provides a rapid solution as to how and where a ligand binds in a 
receptor and predicts key interactions important for ligand recognition. Besides scoring functions the 
obtained ligand docking pose is evaluated based on its agreement with mutagenesis data and 
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structure-activity relationships (SARs) of the ligands. GPCR docking has been recently reviewed in 
several studies (Costanzi. 2013;Beuming et al. 2015;Weiss et al. 2016;Levit et al. 2012). An ability to 
explain experimental data and accurately predict the results of new experiments defines the quality 
of receptor modelling.           
In this chapter, we will focus on molecular modelling of the FFA structures and ligand binding using 
available structural information, mutagenesis data and ligand SARs. We will analyze the recently 
published FFA1 crystal structure and assess past and future modeling of ligand interactions at FFA1. 
We then examine the application of available structural templates in modelling of structures and 
prediction of ligand-receptor interactions for other FFA receptors. In the text, we will provide the 
Ballesteros-Weinstein index (Ballesteros and Weinstein. 1995) for residues in the transmembrane 
helices as a superscript. This index represents X.Y, where X is the helix number and Y is the residue 
number relative to position 50, which is assigned to the most conserved residue in a given helix.  
_______________________________________________________________________________ 
Figure 1: A phylogenetic tree of the rhodopsin family of GPCRs. The phylogenetic tree was 
constructed using the sequence of the transmembrane helices by the online GPCRDB server 
(www.gpcrdb.org). The circular tree type, Neighbour-joining distance calculation and no bootstrapping 
options were used. Clusters to which the free fatty acid receptors belong are highlighted.  
 
 
______________________________________________________________________________ 
 
Free Fatty Acid Receptor 1 
 
X-ray crystallography of FFA1  
 
In 2014 a X-ray crystallographic structure of the human FFA1 in complex with the ago-allosteric ligand, 
TAK-875 provided unprecedented three-dimensional insight into molecular recognition at FFA1 
(Srivastava et al. 2014). The crystal structure revealed that TAK-875 binds to the site involving 
transmembrane helices 3-5 and the second extracellular loop (EL2). In the binding site the oxygen 
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atom of the carboxyl group of the ligand forms hydrogen bonds with two arginines R1835.39 and 
R2587.53, whereas the other one is in H-bonding with two tyrosines, Y2406.51 and Y913.37; the 
dihydrobenzofuran ring of TAK-875 is stabilized via π-π stacking with W174EL2 and F142EL2; the 
biphenyl scaffold protrudes into the interhelical gap between helices 3 and 4; and the methylsulfonyl 
linker is pointed to the extracellular side (Figure 2A and B).  
Interestingly, the guanidium side chains of R1835.39 and R2587.53 are in an unusual charge pairing 
interaction. Despite being both positively charged residues, these arginines do not repulse but are in 
planar stacking with the distance between the Cζ-Cζ atom pairs of 3.6 Å. From the detailed analysis 
of the crystal structure it becomes clear that the electrostatic repulsion between positively charged 
guanidium groups is balanced by the surrounding environment. The counter-ion from the aspartate 
acid residue E172EL2 forms an ionic bridge with R2587.53, interacting with two hydrogens of the 
guanidium (Figure 2C). Two other guanidinium donors of R2587.53 are involved in a direct H-bond with 
Y2406.51 and through a water-mediated hydrogen bond with N2446.55. In the case of R1835.39, two 
guanidinium donors of R1835.39 form a direct hydrogen bond with the backbone of L171EL2 and a 
water-mediated H-bond with the backbone of W174EL2 and E172EL2. Considering that the guanidium 
group can be involved in five hydrogen bonds, R2587.53 and R1835.39 have one and three guanidinium 
donors, respectively, that are free from interactions and could coordinate the carboxyl group of a 
ligand. (Figure 2). Indeed the carboxyl group of TAK-875 forms one hydrogen bond with R2587.53 and 
two hydrogen bonds with R1835.39, thus fully balancing the arginine pairing.  
Although this is the first arginine pairing observed in GPCRs, arginine-arginine short-range 
interactions are found in many other proteins, where these residues are involved in binding of 
nucleotides, organic acids and other negatively charged bioactive molecules. From analysis of 67,520 
crystal structures containing clusters of positively charged arginines, Neves and colleagues (Neves 
et al. 2012) demonstrated that guanidium groups tend to sit in polar pockets or are exposed to solvent. 
In a much earlier study, computer simulations of Magalhaes and colleagues (Magalhaes et al. 1994) 
have predicted the importance of solvent environment for arginine pairing. Similar to other proteins, 
the two pairing arginines in FFA1 are solvent exposed and have interactions with hydrophilic residues. 
It is believed that controlling a counter-charge in arginine-arginine interactions represents a biological 
regulatory mechanism. I propose here that stabilising the arginine-arginine pairing might be crucial 
for activation of FFA1.  
In addition to water molecules involved in the arginine pairing, several other water molecules in the 
binding site are observed in the crystal structure of 2.33 Å resolution (Figure 2C). Although water 
molecules do not interact with the ligand directly, they are engaged in an H-bonding network with the 
residues of the binding site. There are three water molecules with a low B factor that are engaged in 
several hydrogen bonds with the receptor (Figure 2C).  One water molecule links R2587.53 via a water-
mediated interaction with N2446.55, the second water molecule is within the extracellular tip of helix 7 
and the third water molecule is trapped in EL2. With a recognized importance of water molecules in 
GPCRs (Mason et al. 2012), it is likely that ordered water molecules found in the FFA1 binding site 
could also play a critical role in ligand binding and receptor modulation.        
Our recent examination of the crystal structure has revealed K622.60, as a third positively charged 
residue in the binding cavity of FFA1 (Tikhonova and Poerio. 2015). This residue is in the binding site 
due to a proline kink causing unwinding of helix 2. Notably, the residue in the same position in the 
peptide (PAR1, opioid and CXCR4), lysosphingolipid (S1P1) and nucleotide (P2Y12) receptor crystal 
structures contributes to ligand recognition.  
The intracellular side of helix 6, which is known to move away from the helical bundle during receptor 
activation (Rasmussen et al. 2011), is in the inward position, suggesting that the FFA1 receptor in the 
crystal structure is in the inactive state.  
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Four point mutations, A88F, L42A, G103A and Y202F were made to improve expression and thermal 
stability of FFA1 for crystallization. The alanine mutation at position 3.34 is located close to TAK-875 
(5 Å). Our docking study indicates that phenylalanine of the wild type at this position slightly changes 
a docking position of the biphenyl moiety of TAK-875 (Tikhonova and Poerio. 2015).  
 
 
_________________________________________________________________________ 
Figure 2. The binding mode of TAK-875 in the crystal structure of FFA1. A: The overall view of the 
binding site. B: The zoomed view of the H-bonding between the carboxyl group of TAK-875 and four 
residues of the binding site. C: The binding site of TAK-875 in the presence of water molecules. 
Hydrogen bonds and π-π stacking are in pink and blue, respectively. The crystal water molecules are 
shown in light cyan and the water molecules with a low B factor are shown in dark cyan. Residues 
involved in ligand binding, water-mediated interactions and coordination of the arginine pairing; as 
well as used in site-directed mutagenesis are shown in stick-like representation. Numbering of 
receptor helices in Roman numerals.  
 
 
 
 
 
 
Molecular Modelling of FFA1 
 
The FFA1 X-ray structure follows upon a nearly decade long progression of knowledge of the binding 
site at FFA1 and other structural features based on homology modelling and mutagenesis. The first 
structural model of FFA1 was obtained through an iterative approach that combined rhodopsin-based 
homology modelling and receptor mutagenesis (Tikhonova et al. 2007). Rhodopsin, a light-activated 
receptor found in retinal rod cells was a single template available in 2007 to model GPCRs before 
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breakthroughs in GPCR crystallography. Although, the sequence identity in the transmembrane 
helices with FFA1 is only 16%, the first model of FFA1 helped to identify the putative binding cavity 
within helices 3, 4 and 5 and the positively charged residues R1835.39 and R2587.35 anchoring the 
negative carboxylic group of agonists. The homology model in conjunction with mutagenesis also 
predicted Y913.37, Y2406.51, N2446.55, H1374.56 and L1865.42 to form interactions with an agonist. From 
the available FFA1 crystal structure bound to TAK-875 it is clear that Y913.37 and Y2406.51 are in H-
bonding with the carboxyl group of the ligand and not in aromatic and hydrophobic contacts, as it was 
predicted in homology modeling; and H1374.56, L1865.42 and N2446.55 do not form a direct contact with 
the ligand. Overall, the hydrophobic tail of the ligand is pointed to the gap between helices 3 and 4 
and not situated inside the helical bundle as was previously predicted.  
Because EL2 is buried into the helical bundle in rhodopsin and prevents ligand interactions with the 
anchoring residues, the first FFA1 model was built without involvement of EL2 (Tikhonova et al. 2007). 
The next model of FFA1 was constructed using a template based on the β2 adrenergic receptor, the 
first GPCR with a diffusible ligand crystallized (Sum et al. 2009). Although, there is also a low 
sequence conservation in the transmembrane region (18 %) and no homology in EL2, the β2 
adrenergic-based model allowed mapping the solvent accessible orientation of EL2 and made 
predictions of ionic interactions between two glutamates, E145 and E172 of EL2 and two arginines, 
R1835.39 and R2587.35 of transmembrane helices. Molecular dynamics (MD) simulations of the 
receptor and mutagenesis of E145EL2 and E172EL2 suggested that these ionic interactions play roles 
of ionic locks keeping the receptor in an inactive state and breaking upon receptor activation.  The 
FFA1 crystal structure has confirmed the existence of the ionic interaction between E172EL2 and 
R2587.35 (Figure 2). However, it remains unclear whether this ionic interaction breaks upon activation, 
as the available crystal structure is an inactive conformation of the receptor. E145EL2 is outside of the 
binding cavity and in H-bonding with S178EL2 in the experimental structure (Figure 2A).  
FFA1 homology modeling based on the templates with 16-18 % sequence identity helped to map the 
ligand binding area and anchoring residues but were not precise in predicting the type of interactions 
and the ligand-binding mode (Tikhonova and Poerio. 2015). This conclusion fits to the results of 
community-wide GPCR homology modelling assessments conducted by the Abagyan and Stevens 
labs (Michino et al. 2009;Kufareva et al. 2011;Kufareva et al. 2014). According to GPCR homology 
modeling assessments, templates with a sequence identity of at least 30-35 % allow building accurate 
homology models (Michino et al. 2009;Kufareva et al. 2011;Kufareva et al. 2014).   
 
 
Docking to the FFA1 crystal structure. 
 
The crystal structure of FFA1 provides a good starting point for ligand docking. In our recent work we 
have used different docking protocols including standard docking, induced fit docking and docking to 
conformations obtained from conformational search of the binding site residues to explore docking of 
linoleate, GW9508, TUG-770, AMG837, AM1638 and AM8182 in the wild type receptor (Tikhonova 
and Poerio. 2015). The carboxyl group of all the compounds is coordinated by two arginines and two 
tyrosines in all docking studies, similar to TAK-875. However, there is a difference in position of the 
hydrophobic tail of the ligands. While a standard docking protocol with a rigid receptor enables a TAK-
875-like binding mode for most of the agonists, in which the hydrophobic tail is in the interhelical gap 
between helices 3 and 4, docking to the flexible receptor predicts, in addition, a new binding mode, 
where the hydrophobic tail of the agonists is pointed to the gap between helices 4 and 5. Whether it 
is an artefact of docking or this mode truly exists could be further validated by receptor mutagenesis. 
For example, residues facing one of the interhelical gaps could be mutated to bulky ones so that they 
provide hindrance in binding to one gap and validate binding to another gap. 
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Figure 3 shows different binding modes on the example of linoleate. For linoleate, in addition to two 
modes of binding in the gaps between helices (Figure 3A and 3B), there are two other possible binding 
modes (Figure 3C and 3D). In one of the modes, the carboxyl group has the same interactions with 
four residues but the hydrophobic tail is within the helical bundle, around helices 1, 2 and 7. In another 
mode, the carboxyl group forms H-bonding with arginines from the extracellular side and the rest of 
the molecule occupies the sites of water molecules protruding between helices 6 and 7. Although 
docking of flexible linoleate is the least reliable, it helps to generate hypotheses as to how agonistic 
activity of linoleate could be amplified by synthetic agonists, like TAK-875, at a structural level. For 
example, targeting arginines from the extracellular side by substituting existing water-mediated 
contacts could still leave a possibility of targeting the arginines from the side involved in interactions 
with tyrosines.         
Interestingly, docking of bulky AM1638 does not allow to place the ligand between helices in either 
way and gives a solution where the ligand is located within the extracellular side (Tikhonova and 
Poerio. 2015). Since mutagenesis studies suggests that AM1638 does not bind to the arginines (Lin 
et al. 2012;Luo et al. 2012), the carboxyl group of AM1638 might be coordinated by other charged or 
hydrophilic residues within the extracellular binding cavity.   We have previously shown that K622.60 is 
the third positively charged residues in the extracellular side and potentially could interact with 
AM1638 (Tikhonova and Poerio. 2015).  
The fact that the ligands could have different binding modes and occupy different binding sites at 
FFA1 can be also seen from a site map search (Schrodinger, LLC, New York, NY, USA. 2014b) 
(Figure 3). This computational technique is able to add dummy atoms and cluster contiguous dummy 
atoms into a putative site in several areas of the FFA1 extracellular binding cavity: sites around the 
arginine pairing and a site within helix 2 and 7, involving K622.60.    
The use of X-ray structural data is now able to provide greater insight into ligand recognition than 
earlier approaches. Given that four residues are involved in coordination of the carboxyl group of an 
agonist we could hypothesize that there could be more variation allowed in distances between ligand 
coordinating atoms of the residues than if only one residue, an arginine, chelates the carboxyl group 
(see the example with GPR120). Therefore, substitution of the carboxyl group to non-classical 
bioisosteric groups could likely be more tolerated, providing a new route to further modify agonists 
and improve ligand selectivity. Examination of available structures of antagonists (Holliday et al. 2012) 
shows that antagonists either do not have a carboxyl group in the structure or have a carboxyl group 
that is less approachable. This suggests that antagonists likely do not have interactions with the four 
anchoring residues or have interactions with only a few of them.      
In summary, new mutagenesis efforts will be instrumental in mapping the precise binding mode of 
orthosteric and allosteric agonists and antagonists. The recent development of a florescent agonist 
could further assist in distinguishing between orthosteric and allosteric sites at FFA1 (Christiansen et 
al. 2016). The crystal structure is also helpful in initiation of MD simulation studies to probe flexibility 
of the receptor and explore the dynamics of the arginine pairing and the surrounding H-bonding 
network in relation to ligand binding and receptor activation. In addition, simulations of the empty form 
of the receptor could help to clarify the position of helix 4 and therefore the dynamics of the interhelical 
gaps, further clarifying the possibility of different ligand binding modes.    
 
 
_________________________________________________________________________ 
Figure 3: Putative binding sites in FFA1. A-D: Docking solutions for linoleate binding at FFA1. E: The 
surface-based representation of the FFA1 extracellular cavity with contiguous dummy atoms that 
define the putative binding sites. Prediction of the binding sites was made with the Site Map 
(Schrodinger, LLC, New York, NY, USA (2014b) SiteMap 3.3). The surface is colored based on the 
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electrostatic potential.  Hydrogen bonds are in pink. Numbering of receptor helices in Roman 
numerals.  
 
 
 
 
 
 
Free Fatty Acid Receptor 2 
 
The initial structural model of FFA2 was built based on the crystal structure of the β2 adrenergic 
receptor with sequence identity of 18 %. This model, in conjunction with mutagenesis, was used for 
an understanding of the structural basis of selectivity at FFA2/FFA3 (Schmidt et al. 2011) and FFA2 
species orthologues (Hudson et al. 2012) for short carboxylic acids; elucidation of molecular 
determinants in binding of potent synthetic agonists, cmp 1 and cmp 2 in human and rodent 
orthologues of FFA2 (Hudson et al. 2013); and identification of possible ionic locks of activation 
(Hudson et al. 2012), similar to FFA1.   
The recently published crystal structure of FFA1 provides a more suitable template for the modelling 
of FFA2. FFA1 and FFA2 share 32 % sequence identity and have conserved anchoring residues for 
the carboxylate of the ligand. It should be noted, however, as receptor subtypes they have relatively 
low sequence identity in comparison with the adrenergic, muscarinic and opioid receptor subtypes, 
which have over 60 % sequence identity. This could suggest more structural divergence in the ligand 
binding site between FFA1 and FFA2.  Indeed, our recent modelling study suggests that the FFA2 
binding cavity is notably smaller than in FFA1 as a result of a more intensive H-bonding and aromatic 
network, created by non-conserved residues (Tikhonova and Poerio. 2015). In terms of 
physicochemical properties the FFA2 binding site is more aromatic compared to FFA1 and FFA3. 
Redocking of selective carboxylic acids to the new FFA2 model and comparison with the FFA1-based 
FFA3 model suggest that Y903.33, I1454.61 and E166EL2 in FFA2 (F963.33, Y1514.61 and L171EL2 in FFA3) 
are likely responsible for ligand selectivity at FFA2/FFA3 (Tikhonova and Poerio. 2015).  
We compare docking of cmp 1, an agonist and CATPB, an antagonist in the new FFA1-based 
homology model in Figure 4. Similar to FFA1, the carboxylate of the agonist can form interactions 
with two arginines and two tyrosines (Figure 4). In contrast, docking of CATPB predicts that the 
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carboxylate could form interactions with only the arginines. More importantly, a recent mutagenesis 
study suggests that CATPB preferably binds to R2557.35, whereas GLPG0974, another antagonist 
binds to R1805.39 (Sergeev et al. 2016).  It appears that the carboxylate of the agonists and antagonists 
differently coordinate the arginine network of interactions. While agonists are able to be in H-bonding 
with two arginines and two tyrosines, antagonists are unable to form interactions with all the residues. 
Like in FFA1, I suggest that modulation of the arginine pairing is critical in triggering receptor 
activation. The arginine pairing in FFA2 is also stabilized by counter-charged E166EL2 similar to FFA1.   
A different H-bonding network of the carboxylate in agonists and antagonists is likely due to variation 
in the hydrophobic and aromatic moieties. Docking predicts the position of the phenylthiazole moiety 
of cmp1 pointing towards helices 4 and 5 and the remaining group is directed towards helices 3 and 
4 (Figure 4A). Two aromatic moieties of CATPB are pointed in similar directions (Figure 4B). Unlike 
FFA1, it appears that the interhelical space of helices 3 and 4 is less accessible. Although, it seems 
that the conformationally-restricted phenylthiazole moiety by an ortho substituent in the phenyl ring 
stabilizes the position of the carboxylate in the agonist to be able to form H-bonding with four polar 
residues, the precise position of this moiety needs to be further validated by mutagenesis.  
Finally, the FFA1-based homology model of FFA2 was helpful in understanding a two-step activation 
process of 4-CMTB (also known as AMG7703) (Grundmann et al. 2016) at a molecular level.  
Innovative label-free biosensors and functional assays have shown that 4-CMTB briefly activates the 
receptor through the orthosteric site and subsequently induces prolonged activation through the 
allosteric site. We used the new FFA2 homology model to identify interactions of 4-CMTB with the 
orthosteric and allosteric sites and to characterize a precise scenario of dynamic binding that 
highlighted key interactions with the receptor, using steered MD simulations. In particular, the new 
model has helped to establish four residues S863.29, Y903.33, I1454.61 and E166EL2 in the orthosteric 
site and K652.60 in the allosteric site (Figure 4C and 4D). Similar to FFA1, K652.60 is within the binding 
cavity and not outside as it was predicted in earlier models based on the β2 adrenergic receptor.  
Simulations of 4-CMTB binding and unbinding suggested the ligand enters the receptor through the 
extracellular tips of helices 4 and 5, moves to the orthosteric site composed of S683.29, Y903.33, I1454.61, 
H2426.55 and R1805.39 and subsequently, with the help of the inter-site translator residues Y165EL2 and 
Y903.33, occupies the allosteric site by interacting with K652.60. The obtained allosteric binding pose of 
4-CMTB is consistent with the SAR studies (Smith et al. 2011;Wang et al. 2010). In the binding site 
the carbonyl group of the amide group of 4-CMTB forms H-bonding with K652.60 while the hydrogen 
of the amide group forms an H-bond with the backbone of C164EL2. The importance of the amide 
group to act as a hydrogen bond acceptor and donor in binding of 4-CMTB to the receptor is confirmed 
by the absence of activity for analogues containing amino or methylamide groups (Smith et al. 
2011;Wang et al. 2010). The isopropyl moiety of 4-CMTB sticks to helices 2 and 3 forming 
hydrophobic interactions with L612.56, W75EL1, T853.28, F893.32 and the hydrophobic tail of K652.60. The 
small hydrophobic pocket does not allow growing the isopropyl group. Indeed, replacement of the 
isopropyl group for bulkier groups led to reduction of potency (Smith et al. 2011). The polar thiazole 
ring of 4-CMTB is pointed to the extracellular side and in π-π stacking with F73EL1. The contribution 
of the aromatic interaction to the potency of the ligand is demonstrated by the absence of activity for 
an analogues with acetylaminoethyl and cyclooctyl groups (Smith et al. 2011). The remaining phenyl 
group of 4-CMTB is pointed towards the region covered by EL2 and is in hydrophobic and aromatic 
interactions with Y165EL2 and Y903.33.    
Overall, the homology model built based on a template with sequence identity of 32 % together with 
mutagenesis data enabled the characterization of binding of orthosteric agonists and antagonists as 
well as a first sequential activator. Unequal binding to two arginines suggests that planar pairing of 
arginines is differently stabilized in the presence of agonists and antagonists and could be crucial for 
receptor activation.  
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_______________________________________________________________________________ 
Figure 4: Ligand binding at FFA2. A: The agonist binding mode using the example of cmp 1 (Hudson 
et al. 2013). B: Antagonists binding mode using the example of CATPB. C-D: the binding mode of 4-
CMTB in the orthosteric and allosteric sites. Hydrogen bonds, hydrophobic interactions are in pink 
and yellow, respectively. 
 
 
 
 
 
 
Free Fatty Acid Receptor 3  
 
FFA3 has higher sequence identity in the transmembrane domains with FFA2 (49 %) than with FFA1 
(33%). The first model of FFA3 was constructed based on the β2 adrenergic receptor and used for an 
understanding of a preference in binding of short carboxylic acids with sp3 over sp2 hybridized alpha-
carbons (Hudson et al. 2012).   
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The recently available FFA1 crystal structure provides a better quality template for FFA3 modelling. 
Like in FFA1 and FFA2, this receptor has two conserved arginines and two tyrosines for coordination 
of the carboxyl group, suggesting a similar network of interactions, involving the arginine pairing 
(Figure 5). Interestingly, FFA3 has L171EL2 instead of glutamate of FFA1 and FFA2, indicating that 
this residue cannot be around the arginines to stabilize the planar pairing.  It is likely that the 
conformation of EL2 in FFA3 should be notably distinct from FFA1 and FFA2, bringing available 
hydrophilic or negatively charged residues of EL2 close to the arginine pairing to balance this 
interaction. Indeed, there is low sequence homology in EL2 with FFA1. In the binding site of FFA3, 
there is a third arginine at position 2.60, contrasting with a lysine residue at this position in FFA1 and 
FFA2. The role of this residue in receptor function is unclear, however it likely contributes to ligand 
recognition, similar to a lysine in FFA2, and is clustered with other two arginines in planar pairing, due 
to close spatial proximity, thus potentially modulating receptor activation.  
The medicinal chemistry of FFA3 is the least developed of the two subtypes, with only a series of 
allosteric modulators with modest activity available to date. Pharmacological studies have shown that 
mutation of R1855.39 and R2587.35 to alanine does not change the binding of these compounds 
(Hudson et al. 2014). To further assess the recognition of these aromatic compounds by FFA3 
residues F963.33, Y1003.37, Y1514.61, Y170EL2 and F173EL2 forming a putative binding site could be 
mutated.  
With availability of a reasonable homology model of FFA3 progress in the development of ligands 
could be accelerated in the years to come. Indeed, the structural data allows a move from traditional 
high-throughput screening methods to cheaper and efficient virtual screening approaches for the 
identification of novel ligands. In the recent study Huang and colleagues have used homology models 
of the poor-characterized receptors, GPR68 and GPR65 for virtual screening and identified potent 
ligands (Huang et al. 2015). A similar approach could be applied for FFA3 to find potent modulators 
for future pharmacological and modelling studies of the receptor.    
 
 
 
Figure 5: The extracellular binding cavity of FFA3. The residues anchoring the carboxyl group of free 
fatty acids, L171 of the second extracellular loop and R712.60, the third positively charged residue in 
the extracellular binding cavity are visualized.   
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Free Fatty Acid Receptor 4 (GPR120) 
 
Although GPR120 binds long- and medium-chain fatty acids like FFA1 as well as some synthetic 
FFA1 agonists, the anchoring site for the carboxylate and the overall location of the binding site are 
distinct. While two arginines and two tyrosines of FFA1 are involved in coordinating one of the oxygen 
atoms of the carboxylate, these residues are absent in GPR120. Instead, R992.64 chelates the 
carboxylic group of the ligand by forming two hydrogen bonds as predicted initially by the rhodopsin-
based homology model of GPR120 (Negoro et al. 2010;Takeuchi et al. 2013). The binding site is 
located in the centre of a helical bundle involving helices 2, 3, 5, 6 and 7 (Hudson et al. 2014) (Figure 
6A). This is different from FFA1, where the TAK-875 binding site is on the side of the extracellular 
cavity within the helical bundle and is created by helices 3, 4, 5 and 6 (Figure 3E).  
Recently docking of several agonists to the GPR120 homology model built based on the β2 adrenergic 
receptor active state (24 % sequence identity) and supported by residue mutagenesis has been 
reported by Hudson and colleagues (Hudson et al. 2014). The authors suggested that besides R992.64, 
W104EL1 is in H-bonding with the caboxylate, while hydrophobic residues F882.53, F1153.29, W2075.38, 
F2115.42, I2806.51, W2776.48, F3037.35 and F3047.36 create a favourable environment for the hydrophobic 
tail of linoleate, TUG891, TUG-670 and GW9508 (Hudson et al. 2014). This study predicts that 
V2125.43 and I2816.52 form a hydrophobic pocket for the methyl group of TUG-891 (Hudson et al. 2014). 
Unlike other ligands GW9508 interacts with F3117.43 and not F882.53, suggesting difference in the 
binding pose. The importance of hydrophilic residues T1193.33, T3107.42 and N2155.46 in ligand binding 
is also demonstrated.  
Recent advances in structural biology of GPCRs have provided alternative templates for homology 
modelling of GPR120. Among currently available templates the orexin receptors (OX1 and OX2) have 
recently published crystal structures (Yin et al. 2015;Yin et al. 2016) and the highest sequence 
conservation, 30 % in the transmembrane region.  Moreover,  EL2 of the OX2 receptor has a similar 
length and some similarity (16 %), especially in the region after the disulfide bridge, making OX crystal 
structures more suitable templates than other available GPCR crystal structures. We have built the 
improved GPR120 model using these templates to evaluate the ligand binding site. Unlike the β2-
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adrenergic based model of GPR120 with only the side chain of R992.64 clearly pointing to the centre 
of the extracellular cavity, both the backbone and sidechain of R992.64 is orientated towards the centre 
of the helical bundle (Figure 6B). This somewhat affects ligand docking. Figure 6C shows the docked 
pose of TUG891, in which the carboxyl group only interacts with R992.64. Other contacts are relatively 
similar to the β2- adrenergic based model of GPR120 apart from W2075.38, F3037.35 and F3047.36, 
which are likely have a non-direct effect. The biphenyl moiety of TUG891 is predicted to be placed 
perpendicular to the helix and firmly locked in the pocket between helices 2-3 and 4-5. This pose is 
consistent with SAR data and provides steric reasons why large substitutions in the para position of 
the terminal ring is unfavourable as well as explaining the preference of ortho position of the terminal 
ring over meta or para positions. Comparison of the binding cavities of GPR120 with FFA1 shows 
that the GPR120 cavity is large and likely more exposed to the extracellular side, contrasting with a 
narrow cavity of FFA1 that is covered by EL2 and extends to the interhelical space between helices 
3 and 4 (Figures 6 and 3). In GPR120 the ligand needs to adopt a ‘V’-shape and should be relatively 
short but bulky, while in FFA1 the ligand is longer but needs to be narrower to squeeze between 
helices to adopt a ‘U’-shape.   The new model predicts the side chain of L196EL2 and W198EL2 face 
the binding cavity. W198EL2 is conserved with the OX receptors, suggesting a similar position in 
GPR120.  In the GPR120 model, W198 EL2 is in π-π stacking with W2075.38, a critical residue for ligand 
binding (Hudson et al. 2014).  
The known microswitches of activation and inactivation for the rhodopsin familiy of GPCRs are 
conserved in GPR120, contrasting to other free fatty acid receptors. Thus, W6.48 of the conserved 
`CWxP’ motif, the so-called “toggle switch” of GPCR activation, is conserved in GPR120 and predicted 
to be in close proximity to the ligand. In addition, GPR120 has conserved residues at the D[E]RY 
motif and aspartate at position 6.30,  thus forming a salt bridge, known as an intracellular ionic lock 
that holds an inactive state of the receptor. The tyrosine of “NPxxY” motif of GPR120 is predicted to 
interact with the tyrosine at position 7.53 in the active state, similar to rhodopsin and the β2 adrenergic 
receptor. Therefore, GPR120 likely has a typical mechanism of activation observed in many GPCRs 
of the rhodopsin family.  
The validated GPR120 binding site, together with the improved homology model, could be further 
used for establishing the binding properties of a recently identified antagonist (Sparks et al. 2014) and 
biased agonist (Li et al. 2015). For instance, by introducing modifications in the cholecystokinin 2 
(CCK2) receptor as well as in its biased antagonist suggested by modelling, Magnan and colleagues 
(Magnan et al. 2013) were able to identify the key moiety in the ligand responsible for biased signalling 
and a microswitch of activation, involving M3.32 and Y7.43 that stabilizes the β-arrestin active state 
of the CCK2 receptor. Such a bidirectional study could be explored in GPR120.     
 
______________________________________________________________________________ 
Figure 6: The binding site of FFA4. A: The surface-based representation of the FFA4 extracellular 
cavity.  B: The superimposition of the β2-adrenergic and OX2-based homology models based on the 
backbone of the helices. The models are in pink and cyan ribbons, respectively. C: The binding mode 
of TUG891. R992.64 coordinates the carboxylate of TUG891. The surface is colored based on the 
electrostatic potential.   
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GPR84 
The first attempt to delineate the binding site of GPR84 has been made recently by Nikaido and 
colleagues (Nikaido et al. 2015). They used a GPR84 homology model based on a β2 adrenergic 
template with 20 % sequence conservation to predict and then validate by mutagenesis the putative 
residues interacting with decanoic acid, a native agonist and diindolylmethane, a synthetic agonist. 
They found that mutations of L1003.32, F1013.33 and N1043.36 dramatic altered potency of decanoate. 
However, these residues are not important for binding of diindolylmethane. The authors suggested 
that N1043.36 plays an anchoring role for the carboxylate of the ligand at GPR84.  
To further explore the properties of this receptor we modelled its structure using the recently published 
crystal structure of the OX1 receptor (Yin et al. 2016), the template with highest sequence identity, 
31%. Importantly, the sequence analysis of EL2 among the receptors with available crystal structures 
shows that EL2 of GPR84 has 35 % identity and a similar length with rhodopsin (Figure 7A). This is 
interesting, as generally EL2 is quite divergent, even within the same receptor family. From such 
relatively high similarity we could suggest that EL2 of GPR84 has a similar β-sheet conformation and 
covers the cavity within the helical bundle like in rhodopsin. We modelled the GPR84 structure using 
a hybrid template, where EL2 of rhodopsin was attached to the OX1 crystal structure. The obtained 
model was subjected to a short optimization using molecular mechanics and dynamics tools of 
MacroModel (Schrodinger, LLC, New York, NY, USA. 2014a). The resulting model is shown in Figure 
7B and 7C. The model predicts that R172 of EL2 is pointing into the binding cavity within the helical 
bundle and might play a coordinating role for the carboxylate of the ligand. This residue could not 
have been predicted with the β2 adrenergic receptor template used by Nikaido and colleagues 
(Nikaido et al. 2015) due to the absence of any similarity in EL2.  In addition, there are several residues 
with H-bonding capability such as Y812.65, Y692.53, N1043.36, Y1865.45, N3396.55 and H3527.36 in the 
putative ligand binding site. Interestingly, asparagine in position 6.55 is conserved with the OX1 
receptor in which it forms H-bonding with the ligand. Overall, the putative binding site is located at the 
centre of the binding cavity within the helical bundle and is created by aromatic residues, F170EL2, 
F1013.33, F3356.51 and W3607.43, and aliphatic residues, L732.57 and L1003.32. Unlike FFA1-4, GPR84 
has a few aliphatic residues in the binding cavity.  
From sequence analysis and homology modelling it is evident that the ligand binding site of GPR84 
is distinct from FFA1-4. GPR84 does not contain positively charged residues at positions 5.39 and 
7.35 like in FFA1-3 or at position 2.64 like in FFA4. Moreover no charged residues are found in the 
transmembrane bundle facing the putative binding cavity. The improved homology model based on 
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the hybrid template predicts that EL2 could play an important role in anchoring a free fatty acid at 
GPR84 by means of a positively charged arginine. Given that phylogenetically GPR84 belongs to the 
prostanoid receptor subfamily, for which the positively charged residue is predicted to coordinate the 
negatively charged ligands, as exemplified by the prostacyclin receptor (Stitham et al. 2003) it is 
suggested that GPR84 also could attract the anionic part of the ligand via a counter-charged residue.  
 
 
_______________________________________________________________________________ 
Figure 7. A GPR84 homology model. A: The sequence alignment of the second extracellular loop 2 
(EL2) for GPR84 and rhodopsin. The putative anchoring R172EL2 and the corresponding residue in 
rhodopsin is highlighted. B: A homology model based on a hybrid template involving the OX1 receptor 
and EL2 of rhodopsin. C: The putative ligand binding cavity of GPR84. Only potentially interesting 
residues for ligand binding are visualized.    
 
 
_______________________________________________________________________________ 
 
 
Summary and future directions  
 
 
The recent progress in GPCR crystallography has enabled the elucidation of the structure of FFA1 
and provided reliable templates (> 30 % sequence conservation) for homology modelling of other free 
fatty acid receptors. The atomic models of the receptors could now be used for an understanding of 
ligand recognition and subsequently, in structure-based ligand design. In particular, it will be important 
to explore the binding modes of ligands with different chemotypes as well as a different 
pharmacological profile (orthosteric agonists and antagonists, allosteric modulators and biased 
ligands) for FFA1, FFA2 and GPR120 using molecular docking in combination with mutagenesis and 
ligand SARs.  This knowledge should pave the way for the discovery of small molecule drugs with 
improved properties with a high chance of success.  
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For FFA3 and GPR84 receptors with a limited number of ligands available to date it will be interesting 
to probe homology models for virtual screening with a hope to identify new binders and therefore to 
increase the arsenal of ligands to study receptor pharmacology and physiology. Structure-based 
virtual screening of chemical libraries using an X-ray structure or even a homology model is now an 
accepted method of discovering new chemotypes in GPCRs (Ngo et al. 2016). Indeed, prior to FFA1 
crystallisation the virtual screening based on the FFA1 homology model led to identification of 15 
compounds acting as agonists, partial agonists and antagonists (Tikhonova et al. 2008). 
FFA1-3 represent the first GPCRs with an unusual arginine pairing interaction. It appears that the 
regulation of this interaction is crucial for defining the pharmacological property of ligands. Further 
studies are required to explore charge pairing of arginines in receptor modulation.    
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